patent blue v 50mg/2ml injection ampoule
guerbet australia pty ltd - patent blue v, quantity: 25 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; dibasic sodium phosphate dodecahydrate - colours the lymph vessels so that they can then be injected with an x-ray contrast medium
patent blue v
promedico ltd - patent blue v sodium - solution for injection - patent blue v sodium 25 mg/ml - other diagnostic agents - marking lymph vessels and arterial regions.marking sentinel nodes before biopsy in patients with operable breast cancer.
bleu patente v guerbet 2.5 g/100 ml inj. sol. s.c. vial
guerbet - sodium patent blue v - eq. patent blue v 50 mg/2 ml - solution for injection - 2,5/100 ml - patent blue v 50 mg - other diagnostic agents
patent blue v
patent blue v -
patent blue sodium injection solution
guerbet - patent blue sodium - solution - 50mg - patent blue sodium 50mg - other diagnostic agents
patent blue v 2.5% solution for injection 2ml ampoules
imported (france) - patent blue v sodium - solution for injection - 25mg/1gram
dbl sodium nitroprusside concentrated injection sodium nitroprusside 25 mg/ml concentrated injection vial
pfizer australia pty ltd - sodium nitroprusside, quantity: 50 mg - injection, solution - excipient ingredients: water for injections - dbl? sodium nitroprusside injection is indicated for:,1. immediate reduction of blood pressure in patients with hypertensive crises. concomitant oral antihypertensive medication should be started while the hypertensive emergency is being brought under control with sodium nitroprusside.,2. producing controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures where surgeon and anaesthetist deem it appropriate.,3. short term therapy of cardiac failure, to enhance cardiac output and lower myocardial oxygen requirements. patients should be commenced on oral therapy as soon as possible.
sodium nitroprusside injection, solution, concentrate
akorn - sodium nitroprusside (unii: eao03pe1tc) (nitroprusside - unii:169d1260km) - sodium nitroprusside 50 mg in 2 ml - sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. sodium nitroprusside is also indicated for the treatment of acute congestive heart failure. sodium nitroprusside should not be used in the treatment of compensatory hypertension, where the primary hemodynamic lesion is aortic coarctation or arteriovenous shunting. sodium nitroprusside should not be used to produce hypotension during surgery in patients with known inadequate cerebral circulation, or in moribund patients (a.s.a. class 5e) coming to emergency surgery. patients with congenital (leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. these rare condition
sodium nitroprusside injection, solution, concentrate
sagent pharmaceuticals - sodium nitroprusside (unii: eao03pe1tc) (nitroprusside - unii:169d1260km) - sodium nitroprusside 25 mg in 1 ml - sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. sodium nitroprusside is also indicated for the treatment of acute congestive heart failure. sodium nitroprusside should not be used in the treatment of compensatory hypertension, where the primary hemodynamic lesion is aortic coarctation or arteriovenous shunting. sodium nitroprusside should not be used to produce hypotension during surgery in patients with known inadequate cerebral circulation, or in moribund patients (a.s.a. class 5e) coming to emergency surgery. patients with congenital (leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. these rare condition
sodium nitroprusside injection
nexus pharmaceuticals inc - sodium nitroprusside (unii: eao03pe1tc) (nitroprusside - unii:169d1260km) - sodium nitroprusside 25 mg in 1 ml - sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. sodium nitroprusside is also indicated for the treatment of acute congestive heart failure. sodium nitroprusside should not be used in the treatment of compensatory hypertension, where the primary hemodynamic lesion is aortic coarctation or arteriovenous shunting. sodium nitroprusside should not be used to produce hypotension during surgery in patients with known inadequate cerebral circulation, or in moribund patients (a.s.a. class 5e) coming to emergency surgery. patients with congenital (leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. these rare condition